Axion BioSystems

Axion BioSystems is a private, revenue-generating company that has established itself as a key provider of sophisticated live-cell analysis instrumentation and consumables for the life sciences research market. The company's core technology platforms—including Microelectrode Array (MEA) systems for electrophysiology, impedance-based cell analyzers, automated live-cell imagers, and cell counters—enable researchers to capture dynamic biological data from complex models like neurons, cardiomyocytes, and organoids. With over 1,000 systems sold and adoption by all top 10 pharmaceutical companies, Axion serves a critical role in the preclinical drug discovery and safety testing workflow, particularly as the industry shifts towards more complex human-relevant models.

Integrated suite of live-cell analysis platforms including Microelectrode Array (MEA) for electrophysiology, impedance-based cell analysis, automated live-cell imaging, and cell counting. Focus on label-free, real-time functional analysis of complex models like neurons, cardiomyocytes, and organoids.

Operates in the competitive life science instrumentation sector, competing directly with large players like Molecular Devices (Danaher), Sartorius, and S-Bio for MEA and cell analysis market share. Differentiation is based on specialized platforms for organoids, a unified software ecosystem, and a focus on user-friendly, integrated functional analysis workflows.